To evaluate the effect of Asgand in management of pre menstrual syndrome

Efficacy of Asgand in Premenstrual syndrome: A Self Controlled Study - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/01/079044

Enrollment

Registered

2025-01-20

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N943- Premenstrual tension syndrome Health Condition 2: N943- Premenstrual tension syndrome

Interventions

Intervention1: Sufoof of Asgand: Sufoof of Asgand will be prepared according to standard method and filled in capsules of 500 mg. 2 capsules will be administered orally thrice daily with milk starti

Eligibility

Inclusion criteria

Inclusion criteria: Both married and unmarried patients in the age group of 18 to 35 years with regular menstrual cycle between 21 to 35 days presenting with symptoms of PMS as per ACOG diagnostic criteria and PMTS scale score more than 7

Exclusion criteria

Exclusion criteria: Patients with Systemic illnesses DM, HTN, TD Organic pelvic pathology, Patient on hormonal therapy in last 3 months , H/O Psychological disorders , Pregnant and Lactating women

Design outcomes

Primary

Measure	Time frame
Reduction in PMTS ScoreTimepoint: During treatment 5th day of every cycle for 3 cycles Post treatment After 1 month	—

Secondary

Measure	Time frame
Improvement in SF 12 scale for QoLTimepoint: During treatment 5th day of every cycle for 3 cycles Post treatment After 1 month	—

Countries

India

Contacts

Public ContactDr Shafiya Roohi

Government Unani Medical College and Hospital

gumcprincipal1975@gmail.com9731628373

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026